Expert-led analysis. Built in SyMAP.
Pharmaceutical pricing
projects, powered by SyMAP.
You bring the pricing question. We model the options and deliver clear recommendations, a decision-ready presentation and access to the scenarios behind the results.
No SyMAP licence required to commission a project.
Start with the decision
Which pricing question are you working on?
From a single asset to a global portfolio, we connect policy, pricing and forecasts in one analysis.
Where is our MFN exposure?
Assess US most-favored-nation (MFN) drug pricing exposure by product and channel under explicit policy scenarios.
You receive Exposure by product, channel and scenario.
Should we sign an MFN agreement?
Compare sign and hold-out options, including pricing commitments and tariff assumptions.
You receive A comparison of the commercial trade-offs.
Which launch sequence protects value?
Test market order and timing with international reference pricing (IRP) and US MFN effects together.
You receive Launch options with their revenue implications.
How will price changes cascade?
Trace generic-entry price reductions across reference markets and test your response.
You receive Exposure over time and pricing options.
Does the asset’s pricing hold up?
Test an acquisition or licensing target’s forecast against MFN and reference-pricing exposure.
You receive Pricing risks to inform the deal decision.
Where is launch commercially viable?
Assess feasible prices, patient uptake and revenue across prospective markets.
You receive Price corridors and market-level forecasts.
MFN analysis distinguishes GENEROUS, the final GLOBE rule, proposed GUARD and company-specific agreements. Explore the policy detail in our MFN Hub
Selected project experience
Analysis built around a real decision.
Delivered by the team that built SyMAP. Meet the team
Acquisition due diligence
Pricing exposure on an acquisition target
for this engagement
- The decision
- A mid-sized pharmaceutical company needed to understand a target’s US MFN exposure and European launch viability before an acquisition decision.
- Our analysis
- We modelled the portfolio and markets using the client’s forecast assumptions, testing exposure and launch options against pricing constraints.
- What it enabled
- Quantified MFN exposure and revenue implications to inform the deal decision.
Global launch strategy
Optimising launch for a US biotech
a ten-year forecast
- The decision
- A US biotech launching a rare disease asset needed a global launch plan that accounted for international pricing and MFN exposure.
- Our analysis
- We used SyMAP’s Optimizer Studio to compare market selection and launch timing across the global forecast.
- What it enabled
- A selective, retimed launch recommendation with reduced projected MFN impact.
Have a similar decision ahead?
Discuss your projectFrom model to meeting
The answer, the reasoning and the working.
A decision-ready deck
A presentation for your board, pricing committee or deal team, with the findings and choices clearly set out.
Strategic interpretation
What the results mean, which assumptions matter and where sensitivities could change the recommendation.
Access to project scenarios
View and explore the simulations and results in SyMAP, with a walkthrough of the analysis.
Choosing a launch strategy
A clear route from the question to the recommendation.
- 01Frame the decision
Which markets, at what price, and when?
- 02Compare the options
Baseline launch · Retimed launch · Selective launch
- 03Explain the trade-offs
Revenue opportunity, IRP effects and MFN exposure.
- 04Set out the recommendation
Preferred approach, sensitivities and next decisions.
Enlarge analysis example Want to update the analysis yourself? A subsequent SyMAP licence lets your team edit and rerun the same models and saved scenarios.
A focused engagement
How a project runs.
Scope the question
Agree the decision, products, markets, scenarios and deadline.
Build the model
Configure your data and assumptions in SyMAP, with the relevant pricing rules.
Compare scenarios
Test the options and the sensitivities that could change the result.
Discuss the results
Review the recommendations, presentation and underlying scenarios together.
What helps us get started?
The decision you need to make, your products and markets, your deadline, and any existing price files or forecasts. We can also source and build reference data.
Continue in SyMAP, if you need to
Your next question can start here.
A project stands on its own. If modelling becomes an ongoing need, licence SyMAP and continue with the markets, products and scenarios already configured.
Explore the SyMAP platformCommissioned projectExpert-led analysis. Explore the results.
Optional platform licenceEdit assumptions. Run the next scenario.
Before you begin
Pricing project FAQs.
A few practical details about working together.
Do we need a SyMAP licence?
No. You can commission a project on its own. A licence is optional if you want your team to edit and rerun models afterwards.
How long does a project take?
Timing depends on the portfolio, markets, scenarios and available data. We agree a timescale when we scope the project.
What access do we get to the model?
You receive access to view and explore the project simulations in SyMAP. Editing and rerunning those models requires a subsequent platform licence.
Can you use our existing data?
Yes. We can start with your price files, forecasts and assumptions, or source and build reference data. The inputs remain visible in the analysis.
Can you review analysis we already have?
Yes. We can independently rebuild an analysis to investigate differences between models or check a result before it reaches a decision-making meeting.
Start with the question
What decision is on your desk?
Tell us what you need to decide and when. We’ll discuss the scope, the analysis and the next steps.